8-K: Sangamo Therapeutics Receives Nasdaq Deficiency Notice for Low Share Price

Sangamo Therapeutics has been notified by Nasdaq that its stock price has fallen below the minimum required bid price of $1.00 per share for continued listing.

Summary

• Sangamo Therapeutics received a notice from Nasdaq on April 24, 2024, stating that its common stock price had closed below $1.00 for the past 30 consecutive business days.
• This notice indicates a failure to meet the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
• Sangamo has 180 calendar days, until October 21, 2024, to regain compliance by maintaining a minimum closing bid price of $1.00 per share for at least 10 consecutive business days.
• If compliance is not achieved by October 21, 2024, Sangamo may be eligible for an additional 180-day period if it transfers its listing to the Nasdaq Capital Market and meets other requirements.
• To qualify for the second compliance period, Sangamo would need to meet the continued listing requirement for market value of publicly held shares and all other applicable initial listing standards for the Nasdaq Capital Market, except for the bid price requirement.
• The company may need to effect a reverse stock split to regain compliance.
• If Sangamo fails to regain compliance or is not eligible for the second compliance period, Nasdaq may delist the company's stock.
• Sangamo can appeal a delisting determination, but there is no guarantee of success.
• The company intends to monitor its stock price and evaluate options to regain compliance.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (Nasdaq deficiency notice) and potential delisting, which is concerning for investors. The company has time to rectify the situation, but the overall tone is negative.

Positives

• Sangamo has been given 180 days to regain compliance, providing time to address the low stock price.
• The company may be eligible for an additional 180-day period to regain compliance if it transfers to the Nasdaq Capital Market.
• Sangamo intends to actively monitor the stock price and evaluate options to resolve the deficiency.

Negatives

• The company's stock price has fallen below the minimum required bid price of $1.00 for 30 consecutive business days.
• There is a risk of delisting from the Nasdaq Global Select Market if compliance is not regained.
• The company may need to undertake a reverse stock split, which can negatively impact shareholder value.

Risks

• There is a risk that Sangamo will not be able to regain compliance with the minimum bid price requirement.
• Delisting from the Nasdaq Global Select Market could negatively impact the company's stock price and investor confidence.
• A reverse stock split, while potentially necessary, could further dilute shareholder value.
• There is no guarantee that an appeal against delisting would be successful.

Future Outlook

Sangamo intends to monitor its stock price and evaluate options to regain compliance with Nasdaq listing requirements, including a potential reverse stock split.

Management Comments

• The company intends to actively monitor the closing bid price of its common stock between now and the Compliance Date and, as appropriate, will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement.

Industry Context

This announcement reflects a common challenge for biotech companies, where stock prices can be volatile and sensitive to clinical trial results and market sentiment. Many companies face similar listing compliance issues.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, face challenges in maintaining stock prices above the minimum bid price required by exchanges like Nasdaq.
• Companies like Athersys and Ocugen have also faced similar delisting notices in the past, highlighting the volatility and risk associated with the sector.
• A reverse stock split is a common strategy used by companies in this situation, but it can be viewed negatively by investors if not accompanied by positive business developments.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may experience uncertainty due to the company's financial challenges.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• Sangamo will monitor its stock price.
• Sangamo will evaluate options to regain compliance with Nasdaq listing requirements.
• Sangamo may need to effect a reverse stock split.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, compliance, stock price, reverse stock split, Sangamo Therapeutics